Physician profile
Mitchell Adams
NPI 1639898950
$952.59
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $328 · 2023: $252 · 2024: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $176.41 | 2023-2024 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $140.93 | 2022-2024 | Farxiga |
| Lilly USA, LLC | $136.96 | 2022-2024 | Mounjaro, Zepbound |
| Amgen INC. | $126.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.51 | 2024 | Jardiance |
| Novo Nordisk INC | $55.81 | 2022-2023 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $39.62 | 2023 | |
| Corium, LLC | $37.06 | 2024 | Azstarys |
| Dexcom, INC. | $35.48 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $19.37 | 2024 | Freestyle Libre 3 |
| Halozyme INC | $15.19 | 2023 | |
| Pfizer INC. | $14.86 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.74 | 2024 | Xifaxan |
| Pharming Healthcare, INC. | $14.68 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.